TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02452307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine
Description: subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine
Description: subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine
Description: subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine
Description: subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage colony stimulating factor (GM-CSF)
Description: intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: epicutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protamin
Description: subcutaneous

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local hyperthermia
Study: NCT01579903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moroctocog alfa (AF-CC)
Description: Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moroctocog alfa (AF-CC)
Description: Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)
Study: NCT00178477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI with breath-holding
Description: Breath holding for diminished tumor motion.
Study: NCT00670553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Study: NCT01848158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Patients randomized to active treatment will receive acupuncture treatment with press needles (small acupuncture needles manufactured with attached bandage that makes the needle flush with skin) at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a seed magnet at ear shen men position for 4 hours on treatment days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Patients randomized to sham treatment will receive sham acupuncture with similarly appearing bandages placed without press needles attached at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a similarly appearing bandage without seed magnet underneath at ear shen men position for 4 hours on treatment days.
Study: NCT01417546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHS-IL-12
Description: NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHS-IL-12
Description: NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHS-IL-12
Description: NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
Study: NCT00786292

Intervention type: OTHER
Group type: OTHER
Intervention: Assisted mechanical ventilation
Description: Patients will be mechanically ventilated with noisy PSV and PSV in random sequence

Intervention type: OTHER
Group type: OTHER
Intervention: Assisted mechanical ventilation
Description: Patients will be mechanically ventilated with noisy PSV and PSV in random sequence
Study: NCT04434079

Intervention type: OTHER
Intervention: Regular critical care
Description: Clinical demographic data, daily and cumulative FB (input minus output) with and without insensible fluid losses, and daily and total BW changes are recorded, as well as survival outcome.
Study: NCT02335619

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early palliative care
Study: NCT02467179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amigo™ Robotic Catheter Manipulation
Description: Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to robotic catheter manipulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Catheter Manipulation
Description: Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to manual catheter manipulation.
Study: NCT04187118

Intervention type: OTHER
Intervention: Quality of life
Description: Quality of life one year post chemo-therapy
Study: NCT01502748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endovascular sampling
Description: Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations: withdrawal of 3ml of blood from vasculature distal to the occlusive thrombus
Study: NCT02254811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: transfer of healthy human gut bacteria to restore the microbiome

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: transfer of healthy human gut bacteria to restore the microbiome
Study: NCT02654886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Resistance Exercise Training: knee extension and elbow flexion each 3 times per week 3 sets each session; 10 reps/set for 6 months~Respiratory muscle strength training: 25 repetitions -twice daily, 6 days/week for 6 months
Study: NCT01866540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUENZ
Description: live attenuated influenza vaccine
Study: NCT00261365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
Study: NCT03533673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACTUS-101
Description: Adeno-associated virus serotype 8 carrying the human GAA gene under the control of the LSP promoter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACTUS-101
Description: Adeno-associated virus serotype 8 carrying the human GAA gene under the control of the LSP promoter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACTUS-101
Description: Adeno-associated virus serotype 8 carrying the human GAA gene under the control of the LSP promoter.
Study: NCT03154866

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus kefiri LKF01 DSM32079
Description: Lactobacillus kefiri LKF01 DSM32079 in drop formulation. 5 drop/daily for 21 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in drop formulation. 5 drop/daily for 21 days
Study: NCT02250742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry needling
Description: Dry needling uses traditional acupuncture needles without injecting any liquid. Dry needling is based on traditional Western medicine whereby the needle insertion sites are located in known anatomical landmarks such as skeletal muscles, fascia and occasionally joints, tendons and bone/tendon junctions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Dry needling uses traditional acupuncture needles without injecting any liquid. Dry needling is based on traditional Western medicine whereby the needle insertion sites are located in known anatomical landmarks such as skeletal muscles, fascia and occasionally joints, tendons and bone/tendon junctions.
Study: NCT03293602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F-MISO PET imaging
Description: F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
Study: NCT00018148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nortriptyline
Description: Dose titrated to 75 mg daily as tolerated combined with transdermal nicotine 21 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal nicotine
Description: Transdermal nicotine 21 mg, titrated down plus placebo
Study: NCT01329315

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BMI-T
Description: Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BMI-C
Description: Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
Study: NCT00754702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity
Study: NCT03695224

Intervention type: DIAGNOSTIC_TEST
Intervention: Topological perception test
Description: Participants' topological perception are tested with self-designed devices. Participants are asked to respond to the figures shown on the screen, and a final score will appear after they finish all the questions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Topological perception test
Description: Participants' topological perception are tested with self-designed devices. Participants are asked to respond to the figures shown on the screen, and a final score will appear after they finish all the questions.
Study: NCT03335384

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Esophageal Balloon
Description: Small flexible catheter with deflated balloon at distal end to be inserted into the esophagus through the nose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gastric Balloon
Description: Small flexible catheter with deflated balloon at distal end to be inserted into the stomach through the nose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasal Pressure Transducer
Description: Pressure transducer inserted into nasal plug
Study: NCT01279434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E plus Pentoxiphyllin
Description: Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Vitamin E 400 mg BD daily for 12 months
Study: NCT01273766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study: NCT01608763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Your Drinking (CYD) personalized feedback intervention
Description: The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Your Drinking (CYD) personalized feedback intervention
Description: The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.
Study: NCT01033981

Intervention type: DRUG
Intervention: Sunitinib
Description: Treatment for mRCC as indication approved and physician criterium
Study: NCT02707627

Intervention type: DEVICE
Intervention: Laser Therapy
Description: Laser therapy is a technology that can be used to treat hypertrophic burn scars.
Study: NCT01608763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Your Drinking (CYD) personalized feedback intervention
Description: The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.
Study: NCT01621737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 42 IU BID for six weeks
Study: NCT02348177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir with ritonavir in 1:1 ratio
Description: During co-treatment of rifampicin containing tuberculosis treatment and lopinavir/ritonavir (4:1) based therapy, additional ritonavir is given to make lopinavir/ritonavir 1:1 ratio

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 4:1
Description: This is the conventional dosing of LPV/r 4:1 for HIV when TB treatment has not been started or has been stopped
Study: NCT02253914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00379535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: potassium iodide
Description: per os

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: per os
Study: NCT00383552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID
Description: MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate MDI (MF MDI)
Description: MF 100 mcg via metered dose inhaler twice daily for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate 10 mcg
Description: F via metered dose inhaler 10 mcg twice a day for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo metered dose inhaler twice a day for 26 weeks
Study: NCT04739644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Specific wrist rehabilitation by WRISTBOT device
Description: The WRISTBOT is a fully backdrivable manipulandum that allows for movements along its 3 Degrees of Freedom (DoFs) in a human-like Range Of Motion (ROM) of the wrist: 62° flexion/extension (FE), -40°/+45° in ulnar/radial deviation (RUD), and 60° pronation/supination (PS). In addition, the robot permits motions along planes that involve combined multi-DoFs movements. Mechanically, the robot was developed to have low values of inertia, emulating the fluency of natural movements. Each DOF is measured by high resolution incremental encoders and actuated by one brushless motor or two in case of the RUD planes, providing both gravity compensation and continuous torque values necessary to manipulate the human wrist joints. Depending on the torques exerted, the device can be used in either active or assistive/passive modality. The system is integrated with a Virtual Reality environment (VR), useful to provide a visual feedback to the user while he/she is requested to complete the tasks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specific wrist rehabilitation performed by the physiotherapist
Description: Passive, active and assisted mobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General rehabilitation
Description: Exercise with elastic bands or weights, exercise of manipulation and dexterity, simulation of daily life activities supervised by the physiotherapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General rehabilitation
Description: Exercise with elastic bands or weights, exercise of manipulation and dexterity, simulation of daily life activities supervised by the physiotherapist
Study: NCT03852602

Intervention type: DRUG
Intervention: Preemptive Analgesics
Description: Analgesic application15 minutes before the treatment

Intervention type: DRUG
Intervention: Control
Description: Analgesic application15 minutes before the end of the treatment
Study: NCT04819217

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Active bamboo charcoal
Description: During this 6 months' trial, eligible 120 patients with eGFR 15 \< eGFR \< 45 ml/min/1.73m2 and UACR \> 100 mg/g will be enrolled and randomized into 4 groups. The patients in group 1 will receive CharXenPlus 4g (with ABC 2g) thrice daily + CharXprob 0.8 g once daily in the initial 3 months. Group 2 will receive CharXenPlus 4g thrice daily in the initial 3 months, and CharXprob 0.8 g once daily in the last 3 months. Group 3 will receive CharXprob 0.8 g once daily in the initial 3 months, and CharXenPlus 4g thrice daily in the last 3 months. Group 4 will only receive CharXprob 0.8 g once daily in the last 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotics
Description: Probiotics
Study: NCT02994238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Health Management Sensor Platform
Description: The Propeller sensor monitors the use of inhaled medications, capturing the date, time, and number of uses. The sensor then transmits this information using Bluetooth to a paired smart phone or hub. Data can be uploaded to the caregiver's smart phone and to the patient's web portal, which their healthcare team will have access to help overall management.
Study: NCT02172430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium powder inhalation capsules
Description: Powder inhalation via the HandiHaler® once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tersigan®
Description: 2 puffs of oxitropium three times daily via MDI
Study: NCT04521790

Intervention type: OTHER
Intervention: support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.

Intervention type: OTHER
Intervention: support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.

Intervention type: OTHER
Intervention: support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
Study: NCT03472625

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening and diagnosis of aphasia, dysarthria, dysphagia
Description: Screening (day 2 +/- 1; day 7 +/-1): NIHSS (National Health Institute Scale) 9 and 10 scores, dysphagia screening (nurse), speech-, and language screening (speech therapist)~Diagnostic assessment (day 2 +/-1-):~Dysphagia: MASA (Mann Assessment of Swallowing Abilities), FOIS (Functional Oral Intake Scale) Dysarthria: perceptual assessment, NSVO-Z (Nederlands spraakverstaanbaarheidsonderzoek - zinnen) Aphasia: ScreeLing, BNT (Boston Naming Test)
Study: NCT00579774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low AGE Diet
Description: Diet
Study: NCT01621737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 84 IU BID for six weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle placebo
Study: NCT00641901

Intervention type: BEHAVIORAL
Intervention: counseling
Description: The 8-week study includes 3 visits to the dental facility at the Center for Women's Reproductive Health at UAB. Study visits are scheduled to coincide with pre-natal visits in the same facility.~Each visit will include individually tailored one-to-one discussion with a dental professional coupled with a demonstration and instructions for using oral hygiene products. Home-care kits will be dispensed, to include a helpful digital video disk (DVD), a high-tech powered toothbrush, dental floss, toothpaste and alcohol-free mouth rinse and subjects will have their teeth professionally cleaned.~First and final visits will include collection of gingival crevicular fluid and blood samples and subjects will complete pre and post study questionnaires.
Study: NCT03910686

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation and cognitive behavioral therapy
Description: Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
Study: NCT00579774

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Diet
Description: Diet
Study: NCT02568969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eirus continuous lactate monitor
Description: a triple-lumen central venous catheter (Eirus TLC) functioning as a regular central venous catheter (CVC) with an integrated microdialysis function will be inserted via the left jugular vein for continuous monitoring of lactate and glucose using Eirus intravascular microdialysis system (Maquet Critical Care, Solna, Sweden) after calibration with arterial sample. Eirus TLC will be used for both drug administration and blood sampling and will be removed postoperatively when a central line will no longer be necessary.